FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313339980> ?p ?o ?g. }

• W4313339980 endingPage "534" @default.
• W4313339980 startingPage "525" @default.
• W4313339980 abstract "Codelivering subunit antigens and Toll-like receptor (TLR) molecular adjuvants via nanocarriers can stimulate potent innate and specific immune responses. Simple and effective nanovaccines fabrication is crucial for application. However, most nanovaccines were fabricated by introducing additional delivery materials, increasing safety risk, cost and processing complexity. Herein, a carrier-free nanovaccine was facilely prepared using a TLR1/TLR2 adjuvant, Diprovocim, rich in benzene rings that could interact with aromatic residues in subunit antigens through π-π stacking without additional materials. The carrier-free nanovaccines with a narrow size distribution could target lymph nodes (LNs) after intravenous injection to mice. The carrier-free nanovaccines based on ovalbumin (OVA) can stimulate strong antibody titers and CD4+ and CD8+ T cell immune responses in mice, and it synergized with anti-PD1 showing a potent tumor suppression in B16F10-OVA tumor model of mice. Furthermore, the carrier-free nanovaccine with glycoprotein E (gE), a glycoprotein of the varicella-zoster virus (VZV), also showed potent humoral and cellular immune responses. Therefore, using subunit proteins to support Diprovocim by π-π stacking provides a new approach for the preparation and application of novel vaccines for tumor therapy and prevention of infectious diseases. Codelivering subunit antigens and adjuvants via nanocarriers stimulate potent innate and specific immune responses. However, existing delivery materials for fabricating nanovaccines will inevitably increase the cost of preparation, controllability, process complexity and safety assessment. Therefore, this study easily prepared carrier-free nanovaccines using the benzene ring-rich TLR1/TLR2 adjuvant Diprovocim, which can interact with aromatic residues in subunit antigens via π-π stacking without additional materials. The carrier-free nanovaccines of OVA demonstrated a potent tumor inhibition in treating melanoma in combination with anti-PD1. And the nanovaccines of gE stimulated a strong antibody titer and cellular immune response for herpes zoster. Thus, the present study provides a new approach for the preparation of subunit vaccines to combat various cancers and virus infections." @default.
• W4313339980 created "2023-01-06" @default.
• W4313339980 creator A5000426662 @default.
• W4313339980 creator A5019552597 @default.
• W4313339980 creator A5043416563 @default.
• W4313339980 creator A5051229707 @default.
• W4313339980 creator A5057287134 @default.
• W4313339980 creator A5074103625 @default.
• W4313339980 creator A5077613732 @default.
• W4313339980 creator A5083733116 @default.
• W4313339980 date "2023-03-01" @default.
• W4313339980 modified "2023-09-28" @default.
• W4313339980 title "Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections" @default.
• W4313339980 cites W1878522445 @default.
• W4313339980 cites W1924252729 @default.
• W4313339980 cites W1987969852 @default.
• W4313339980 cites W1998591071 @default.
• W4313339980 cites W2004773897 @default.
• W4313339980 cites W2024089410 @default.
• W4313339980 cites W2090928701 @default.
• W4313339980 cites W2204416339 @default.
• W4313339980 cites W2227867144 @default.
• W4313339980 cites W2289160872 @default.
• W4313339980 cites W2296598106 @default.
• W4313339980 cites W2337939199 @default.
• W4313339980 cites W2530625287 @default.
• W4313339980 cites W2590023130 @default.
• W4313339980 cites W2600637448 @default.
• W4313339980 cites W2612384787 @default.
• W4313339980 cites W2749726749 @default.
• W4313339980 cites W2760376241 @default.
• W4313339980 cites W2797781913 @default.
• W4313339980 cites W2802211855 @default.
• W4313339980 cites W2888828176 @default.
• W4313339980 cites W2894628232 @default.
• W4313339980 cites W2895497426 @default.
• W4313339980 cites W2896843732 @default.
• W4313339980 cites W2899759826 @default.
• W4313339980 cites W2904297611 @default.
• W4313339980 cites W2915321625 @default.
• W4313339980 cites W2943197912 @default.
• W4313339980 cites W2956357730 @default.
• W4313339980 cites W3011494554 @default.
• W4313339980 cites W3014146450 @default.
• W4313339980 cites W3015371627 @default.
• W4313339980 cites W3016003542 @default.
• W4313339980 cites W3033020580 @default.
• W4313339980 cites W3107412307 @default.
• W4313339980 cites W3112630452 @default.
• W4313339980 cites W3118293151 @default.
• W4313339980 cites W3156555003 @default.
• W4313339980 cites W3164599657 @default.
• W4313339980 cites W3171579200 @default.
• W4313339980 cites W3195601531 @default.
• W4313339980 cites W3197773987 @default.
• W4313339980 cites W4205352274 @default.
• W4313339980 cites W4206413133 @default.
• W4313339980 cites W4220735688 @default.
• W4313339980 cites W4223491824 @default.
• W4313339980 cites W4308289859 @default.
• W4313339980 doi "https://doi.org/10.1016/j.actbio.2022.12.042" @default.
• W4313339980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36572250" @default.
• W4313339980 hasPublicationYear "2023" @default.
• W4313339980 type Work @default.
• W4313339980 citedByCount "0" @default.
• W4313339980 crossrefType "journal-article" @default.
• W4313339980 hasAuthorship W4313339980A5000426662 @default.
• W4313339980 hasAuthorship W4313339980A5019552597 @default.
• W4313339980 hasAuthorship W4313339980A5043416563 @default.
• W4313339980 hasAuthorship W4313339980A5051229707 @default.
• W4313339980 hasAuthorship W4313339980A5057287134 @default.
• W4313339980 hasAuthorship W4313339980A5074103625 @default.
• W4313339980 hasAuthorship W4313339980A5077613732 @default.
• W4313339980 hasAuthorship W4313339980A5083733116 @default.
• W4313339980 hasConcept C104292427 @default.
• W4313339980 hasConcept C104317684 @default.
• W4313339980 hasConcept C136449434 @default.
• W4313339980 hasConcept C147483822 @default.
• W4313339980 hasConcept C171250308 @default.
• W4313339980 hasConcept C178790620 @default.
• W4313339980 hasConcept C18150654 @default.
• W4313339980 hasConcept C185592680 @default.
• W4313339980 hasConcept C192562407 @default.
• W4313339980 hasConcept C203014093 @default.
• W4313339980 hasConcept C2776090121 @default.
• W4313339980 hasConcept C2776946954 @default.
• W4313339980 hasConcept C2777863537 @default.
• W4313339980 hasConcept C2778973524 @default.
• W4313339980 hasConcept C2779820397 @default.
• W4313339980 hasConcept C2781236682 @default.
• W4313339980 hasConcept C33347731 @default.
• W4313339980 hasConcept C55493867 @default.
• W4313339980 hasConcept C83464605 @default.
• W4313339980 hasConcept C86803240 @default.
• W4313339980 hasConcept C8891405 @default.
• W4313339980 hasConcept C95444343 @default.
• W4313339980 hasConceptScore W4313339980C104292427 @default.
• W4313339980 hasConceptScore W4313339980C104317684 @default.

• next